Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 17/20 | 1.00 |
| ▸ | TACR1 | P25103 | 16/20 | 1.00 |
| ▸ | TACR3 | P29371 | 9/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | CCR5 | P51681 | 2/20 | 0.65 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Osanetant SCHEMBL30961738 | 1.00 | TACR2 (1.00) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| Osanetant SCHEMBL4080131 | 1.00 | TACR2 (1.00) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| Osanetant SCHEMBL5679271 | 1.00 | TACR2 (1.00) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| Osanetant SCHEMBL29371450 | 1.00 | TACR2 (1.00) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| Osanetant SCHEMBL5679471 | 0.99 | TACR2 (0.98) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| Osanetant SCHEMBL6543149 | 0.99 | TACR2 (0.98) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL8136920 | 0.97 | TACR2 (0.95) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL6543864 | 0.97 | TACR2 (0.94) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL24855515 | 0.96 | TACR2 (0.92) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL31224281 | 0.96 | TACR2 (0.92) | TACR2TACR1TACR3CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2534 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704271-B1 | NEUROKININ ANTAGONISTS AND USES THEREOF | CALIFORNIA INST OF TECHN (US) | 2026-01-28 | — | — | EP | claimed |
| US-20250270330-A1 | TREATMENT OF HEADACHE DISORDERS WITH NK3 MODULATORS | KALLYOPE, INC. | 2025-08-28 | — | — | US | claimed |
| US-20250250244-A1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | H LUNDBECK AS (DK) | 2025-08-07 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4514351-A1 | TREATMENT OF HEADACHE DISORDERS WITH NK3 MODULATORS | Kallyope, Inc. (US) | 2025-03-05 | — | — | EP | claimed |
| US-20250057830-A1 | NEUROKININ ANTAGONISTS AND USES THEREOF | CALIFORNIA INST OF TECHN (US) | 2025-02-20 | — | — | US | claimed |
| CN-119403555-A | Treatment of headache disorders using NK3 modulators | 卡尔优普公司 | 2025-02-07 | — | — | CN | claimed |
| US-20240336565-A1 | SOLID FORMS OF OSANETANT | ACER THERAPEUTICS INC. | 2024-10-10 | — | — | US | claimed |
| US-12083109-B2 | Neurokinin antagonists and uses thereof | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2024-09-10 | — | — | US | claimed |
| US-20240277729-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS USING AN SGLT-2 INHIBITOR AND A NEUROLEPTIC AGENT | BOEHRINGER INGELHEIM INT (DE) | 2024-08-22 | — | — | US | claimed |
| EP-1299100-A1 | METHOD OF TREATING SYMPTOMS OF HORMONAL VARIATION, INCLUDING HOT FLASHES, USING TACHYKININ RECEPTOR ANTAGONIST | THE UNIVERSITY OF ROCHESTER (US) | 2003-04-09 | — | — | EP | claimed |
| US-20020156067-A1 | New drug combinations | PHARMACIA & UPJOHN COMPANY | 2002-10-24 | — | — | US | claimed |
| US-6420388-B1 | Osanetant in the treatment of depression and depressive disorders | SANOFI-SYNTHELABO (FR) | 2002-07-16 | — | — | US | claimed |
| WO-2002053140-A2 | NEW DRUG COMBINATIONS OF NOREPINEHRINE REUPTAKE INHIBITORS AND NEUROLEPTIC AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-07-11 | — | — | WO | claimed |
| CN-1354662-A | Application of Osmanthodast in medicinal preparation for treating mood diseases | SANOFI SYNTHELABO (FR) | 2002-06-19 | — | — | CN | claimed |
| US-20020016283-A1 | Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist | UNIVERSITY OF ROCHESTER | 2002-02-07 | — | — | US | claimed |
| WO-2001095904-A1 | METHOD OF TREATING SYMPTOMS OF HORMONAL VARIATION, INCLUDING HOT FLASHES, USING TACHYKININ RECEPTOR ANTAGONIST | UNIVERSITY OF ROCHESTER (US) | 2001-12-20 | — | — | WO | claimed |
| CN-1314888-A | Crystalline forms of osanetant | SANOFI SYNTHELABO CO (FR) | 2001-09-26 | — | — | CN | claimed |
| EP-1102747-A1 | CRYSTALLINE FORMS OF OSANETANT | SANOFI-SYNTHELABO (FR) | 2001-05-30 | — | — | EP | claimed |
| WO-2000007987-A1 | CRYSTALLINE FORMS OF OSANETANT | SANOFI-SYNTHELABO (FR) | 2000-02-17 | — | — | WO | claimed |